Competitor Analysis: Targeted Therapy of Hepatitis C
Product description
The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatment, pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted in a further increase in treatment efficiency with 54% of HCV infected patients achieving SVR. The response and rate of SVR is dependent on the genotype of HCV with only 30% of genotype 1 infected individuals achieving SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination therapy. Combination therapy treatment regiments are genotype dependent and the amount of peg-IFN-? administered is dependent on the type used.
The suboptimal response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with frequent side effects and have a negative impact on the patient's quality of life.
The report includes a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. In addition, the report lists company-specific R&D pipelines of targeted therapeutics in hepatitis C. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatment, pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted in a further increase in treatment efficiency with 54% of HCV infected patients achieving SVR. The response and rate of SVR is dependent on the genotype of HCV with only 30% of genotype 1 infected individuals achieving SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination therapy. Combination therapy treatment regiments are genotype dependent and the amount of peg-IFN-? administered is dependent on the type used.
The suboptimal response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with frequent side effects and have a negative impact on the patient's quality of life.
The report includes a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. In addition, the report lists company-specific R&D pipelines of targeted therapeutics in hepatitis C. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and additional comments with a hyperlink leading to the source of information.
- HCV Protease Inhibitors
- HCV RNA Polymerase Inhibitors
- Cyclophilin Inhibitors
- HCV NS5A Protein Inhibitors
- HCV NS4B-RNA Binding Inhibitors
- Therapeutic & Preventative HCV Vaccines
- Therapeutic HCV Antibodies
- HCV Viral Entry Inhibitors
- HCV Replication Inhibitors
- Novel Mechanism of Action HCV Virus & Host Cell Targets
- TLR Agonists
- Various
- Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
- About La Merie
- Abbott
- Achillion Pharmaceuticals
- Alios Biopharma
- Altor Biosciences
- Anadys Pharmaceuticals
- Astex Therapeutics
- Avila Therapeutics
- Bionor Immuno
- Biotica Technology
- Biotron
- Boehringer Ingelheim
- Bristol-Myers Squibb (BMS)
- C-Pharma
- Can-Fite BioPharma
- Chimerix
- ChronTech Pharma
- Compass Biotechnologies
- Conatus Pharmaceuticals
- CureTech
- Cytheris
- Debiopharm
- Dynavax Technologies
- Eiger Pharmaceuticals
- Enanta Pharmaceuticals
- Epiphany Biosciences
- Epixis
- Genmab
- GenPhar
- Gilead Sciences
- GlaxoSmithKline (GSK)
- GlobeImmune
- Heat Biologics
- Idenix Pharmaceuticals
- Idera Pharmaceuticals
- Inhibitex
- Inovio
- Intellektualniy Dialog
- Intercell
- iTherX Pharmaceuticals
- Japan Tobacco
- Johnson & Johnson (J&J)
- Medivir
- Massachusetts Biologic Laboratories (MBL)
- Merck & Co
- Mitsubishi Tanabe Pharma
- Morningside Asia Venture
- Novartis
- Okairos
- Ono Pharmaceutical
- Paladin Biosciences
- Peregrine Pharmaceuticals
- Pfizer
- Pharmasset
- PTC Therapeutics
- Presidio Pharmaceuticals
- Progenics Pharmaceuticals
- Regulus Therapeutics
- Replicor
- Roche
- Rosetta Genomics
- Samaritan Pharmaceuticals
- Santaris Pharma
- SCYNEXIS
- Tacere Therapeutics
- TaiGen Biotechnology
- Teva Pharmaceutical Industries
- Theravance
- Transgene
- Tripep
- Vertex Pharmaceuticals
- Viriome
- Virionics
- ViroBay
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
